Perceptive Advisors’s Abiomed Inc ABMD Stock Holding History

Perceptive Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-50,000	Closed	-$1.9M	–	183
2014 Q4	$1.9M	Buy	+50,000	New	+$1.58M	0.16%	90

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors's ABMD Position: Q4 2018 in Review

Perceptive Advisors sold out of Abiomed Inc (ABMD) in Q4 2018, closing a stake of 23,800 shares — an estimated $10.7M sold.

Perceptive Advisors first reported a position in ABMD in Q1 2014 and held it in 14 quarters. The position peaked at $96.7M in Q1 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q4 2018.

Perceptive Advisors reported no remaining Abiomed Inc position as of Q4 2018 after selling out during the quarter.
Perceptive Advisors sold 23,800 Abiomed Inc shares in Q4 2018, an estimated $10.7M.
Perceptive Advisors first reported a position in Abiomed Inc in Q1 2014 and held it in 14 quarters.
Perceptive Advisors's Abiomed Inc position peaked at $96.7M in Q1 2018.
529 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.